Overview

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd
Treatments:
Valsartan